Protagonist Therapeutics, Inc (PTGX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Protagonist Therapeutics reported revenue of $46.0M, down 89.4% from $434.4M the year before. Net income was -$130.1M (a -282.8% net margin), or -$2.05 per diluted share. Operating margin was -343.6%. Operating activities generated $57.7M of cash, leaving $56.1M of free cash flow. At fiscal year end, Protagonist Therapeutics held $668.2M in total assets against $53.5M in total liabilities, including $128.4M of cash and equivalents.
Open the full interactive Protagonist Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Protagonist Therapeutics Key Stats
| Share Price | $138.49 |
|---|---|
| Market Cap | $9.83B |
| Revenue YoY Growth | -89.4% |
| 52-Week Range | $73.50 – $158.62 |
| Shares Outstanding | 65.9 million (basic, 2026 Q2) |
Protagonist Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $27.4M | $26.6M | $60.0M | $434.4M | $46.0M |
| Operating Income | -$64.5M | -$125.8M | -$131.4M | -$93.7M | $252.8M | -$158.1M |
| Pre-Tax Income | -$64.8M | -$125.6M | -$127.4M | -$79.0M | $279.4M | -$129.3M |
| Income Tax | $1.3M | $0 | $0 | $0 | $4.2M | $838,000 |
| Net Income | -$66.2M | -$125.6M | -$127.4M | -$79.0M | $275.2M | -$130.1M |
| Diluted EPS | -$1.92 | -$2.71 | -$2.60 | -$1.39 | $4.23 | -$2.05 |
Protagonist Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $4.7M | $7.4M | $56.4M | $213.5M |
| Net Income | -$39.3M | -$44.4M | $3.8M | $162.8M |
| Diluted EPS | -$0.62 | -$0.70 | $0.05 | $2.29 |
Protagonist Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $117.4M | $123.7M | $125.7M | $186.7M | $97.2M | $128.4M |
| Current Assets | $315.6M | $340.7M | $243.1M | $355.6M | $591.6M | $577.6M |
| Total Assets | $324.5M | $347.7M | $247.9M | $358.0M | $744.7M | $668.2M |
| Current Liabilities | $40.2M | $44.0M | $31.2M | $21.3M | $47.4M | $45.4M |
| Total Liabilities | $44.9M | $47.7M | $32.3M | $21.3M | $69.4M | $53.5M |
| Shareholders' Equity | $279.6M | $300.0M | $215.6M | $336.7M | $675.3M | $614.7M |
Protagonist Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$72.5M | -$107.9M | -$108.1M | -$70.2M | $184.2M | $57.7M |
| Cash From Investing | -$91.0M | -$15.9M | $91.5M | -$39.3M | -$299.5M | -$49.3M |
| Cash From Financing | $247.6M | $129.9M | $18.8M | $170.5M | $25.9M | $22.9M |
| Free Cash Flow | -$73.0M | -$109.0M | -$108.9M | -$70.8M | $182.8M | $56.1M |
Figures from Protagonist Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Protagonist Therapeutics financials page for every line item.
Protagonist Therapeutics Company Profile
| Ticker | PTGX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Newark, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001377121 |
Frequently Asked Questions
What was Protagonist Therapeutics' revenue in fiscal 2025?
Protagonist Therapeutics (PTGX) reported revenue of $46.0M for fiscal 2025.
What is Protagonist Therapeutics' annual revenue history?
Protagonist Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $27.4M; 2022: $26.6M; 2023: $60.0M; 2024: $434.4M; 2025: $46.0M.
What was Protagonist Therapeutics' net income in fiscal 2025?
Protagonist Therapeutics reported net income of -$130.1M for fiscal 2025.
What was Protagonist Therapeutics' earnings per share (EPS) in fiscal 2025?
Protagonist Therapeutics' diluted EPS was -$2.05 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Protagonist Therapeutics generate in fiscal 2025?
Protagonist Therapeutics generated $56.1M of free cash flow in fiscal 2025.
What was Protagonist Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Protagonist Therapeutics reported revenue of $213.5M.
How many shares of Protagonist Therapeutics are outstanding?
Protagonist Therapeutics reported a weighted average of 65.9 million basic shares outstanding in 2026 Q2.
What is Protagonist Therapeutics' market cap?
Based on its latest closing price, Protagonist Therapeutics (PTGX) has a market capitalization of about $9.83B.
When does Protagonist Therapeutics' fiscal year end?
Protagonist Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Protagonist Therapeutics headquartered?
Protagonist Therapeutics lists its business address in Newark, California in its SEC filings.